Published by Josh White on 18th December 2025
(Sharecast News) - Avacta reported new pharmacology data on its second oncology asset, FAP-Exd (AVA6103), on Thursday, showing sustained tumor exposure and prolonged responses across multiple preclinical models, as the company prepared to begin phase one testing in the first quarter of 2026.
URL: http://www.digitallook.com/dl/news/story/35572066/...